Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

DCOY

D

Decoy Therapeutics Inc. (DCOY)

NCM – Real Time Price. Currency in USD

6.30

-0.72 (-10.32%)

At close: Mar 27, 2026, 4:00 PM EDT

6.49

+0.19 (3.02%)

After-hours: Mar 27, 2026, 5:36 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically increase the speed and scale of antiviral peptide discovery.

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m.

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

- Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform.

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

– Live video webcast on Tuesday, February 10th at 1:20 PM EST CAMBRIDGE, Mass. and HOUSTON, Feb. 5, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation.

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP 3 ACT™ platform for low- and middle-income countries. CAMBRIDGE, Mass.

Videos

No Data

There is no data to display

Press releases

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically increase the speed and scale of antiviral peptide discovery.

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics, today announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m.

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

- Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform.

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation.